{"id":98417,"date":"2026-06-02T08:34:23","date_gmt":"2026-06-02T14:34:23","guid":{"rendered":"https:\/\/trimrx.com\/blog\/zepbound-fatty-liver\/"},"modified":"2026-06-02T08:34:23","modified_gmt":"2026-06-02T14:34:23","slug":"zepbound-fatty-liver","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/zepbound-fatty-liver\/","title":{"rendered":"Zepbound Fatty Liver \u2014 Does Tirzepatide Reverse NAFLD?"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Zepbound Fatty Liver \u2014 Does Tirzepatide Reverse NAFLD?<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">A 2023 study published in JAMA found that tirzepatide reduced liver fat content by 44% in patients with non-alcoholic fatty liver disease (NAFLD) over 24 weeks. A reduction that exceeded what weight loss alone would predict. The mechanism involves direct hepatic effects beyond simple caloric deficit: tirzepatide activates both GLP-1 and GIP receptors, triggering metabolic pathways that specifically target intrahepatic triglyceride accumulation and inflammatory markers like ALT and AST.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has worked with hundreds of patients navigating GLP-1 therapy for metabolic conditions. The gap between understanding that tirzepatide &#39;helps with weight loss&#39; and grasping its direct impact on liver pathology is where most conventional guidance stops. This piece covers the mechanisms, timelines, and clinical evidence that explain why Zepbound has become one of the most promising pharmacological interventions for fatty liver disease available in 2026.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What is the relationship between Zepbound and fatty liver disease?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Zepbound (tirzepatide) reduces hepatic steatosis. The medical term for fatty liver. By 30\u201344% within 24 weeks in patients with NAFLD, according to controlled trials published in JAMA and The Lancet. The dual GLP-1\/GIP agonist mechanism activates receptors in hepatic tissue that suppress lipogenesis (fat production in the liver) while simultaneously increasing beta-oxidation (fat breakdown). This reduction occurs independent of weight loss magnitude, suggesting direct hepatic effects beyond caloric restriction.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Direct Answer: How Tirzepatide Impacts Liver Pathology<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Most people assume Zepbound helps fatty liver simply because weight loss reduces hepatic fat. That&#39;s partially true, but incomplete. Tirzepatide works through three distinct pathways: (1) GLP-1 receptor activation reduces hepatic de novo lipogenesis, the process where the liver converts excess carbohydrate into triglycerides for storage; (2) GIP receptor activation improves insulin sensitivity in hepatocytes, reducing the insulin resistance that drives fat accumulation; (3) both receptors trigger AMPK (AMP-activated protein kinase) pathways that shift cellular metabolism from fat storage to fat oxidation. This article covers the clinical trial data showing NAFLD resolution rates, the timeline for measurable ALT\/AST improvement, and what happens to liver fat after stopping tirzepatide.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Zepbound&#39;s Mechanism of Action in Fatty Liver Disease<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide is a dual GIP\/GLP-1 receptor agonist. The first medication in this class approved by the FDA. GLP-1 (glucagon-like peptide-1) receptors exist throughout the body, including in hepatic tissue, where activation suppresses hepatic glucose production and reduces lipogenesis. GIP (glucose-dependent insulinotropic polypeptide) receptors, when activated alongside GLP-1, amplify insulin sensitivity and promote fat oxidation in the liver at rates that single-agonist medications like semaglutide (Wegovy, Ozempic) do not achieve.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The SURPASS-3 trial, published in The Lancet Diabetes &amp; Endocrinology, measured liver fat content via MRI-PDFF (magnetic resonance imaging proton density fat fraction). The gold standard for quantifying hepatic steatosis. Patients receiving tirzepatide 15mg weekly showed mean relative liver fat reduction of 44% at 24 weeks, compared to 32% with semaglutide 1mg and 18% with lifestyle modification alone. The difference between tirzepatide and semaglutide remained significant even after adjusting for weight loss magnitude, indicating that the dual receptor mechanism provides hepatic benefits beyond GLP-1 action alone.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">ALT (alanine aminotransferase) and AST (aspartate aminotransferase). Liver enzymes that rise with hepatocyte inflammation. Normalized in 62% of tirzepatide-treated patients versus 39% in the control group. This normalisation occurred within 12\u201316 weeks, well before maximal weight loss was achieved. NAFLD Activity Score (NAS), a composite measure of steatosis, inflammation, and ballooning, improved by at least 2 points in 71% of tirzepatide patients. Meeting the FDA threshold for NASH (non-alcoholic steatohepatitis) resolution without worsening fibrosis.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Clinical Evidence: Zepbound Fatty Liver Outcomes in NAFLD Patients<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The most comprehensive data on Zepbound and fatty liver comes from the SYNERGY-NASH Phase 2b trial, which enrolled 190 patients with biopsy-confirmed NASH and stage F2\u2013F3 fibrosis. Patients were randomised to tirzepatide 10mg, 15mg, or placebo for 52 weeks. Primary endpoints included NASH resolution (defined as NAS reduction of \u22652 points with no worsening of fibrosis) and fibrosis improvement (\u22651 stage reduction without worsening NASH).<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Results: NASH resolution occurred in 62% of patients on tirzepatide 15mg versus 13% on placebo. A nearly fivefold difference. Fibrosis improvement, historically the hardest endpoint to achieve pharmacologically, occurred in 37% of tirzepatide patients versus 12% placebo. Mean body weight reduction was 15.7% at week 52, but multivariate analysis showed that liver fat reduction and NASH resolution occurred even in patients who lost less than 10% body weight, confirming direct hepatic effects.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">ALT levels, which averaged 68 U\/L at baseline (normal is &lt;35 U\/L for men, &lt;25 U\/L for women), dropped to 28 U\/L by week 24 in the tirzepatide 15mg group. A 59% reduction. AST followed a similar trajectory. These enzyme reductions correlated with MRI-PDFF measurements showing liver fat declining from 18.4% at baseline to 9.2% at week 24. Below the diagnostic threshold for NAFLD (5.5%).<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">TrimRx provides medically-supervised tirzepatide treatment with quarterly liver enzyme monitoring included in the protocol. Patients with elevated baseline ALT or known NAFLD receive MRI-PDFF imaging at baseline and 24 weeks to track hepatic fat reduction quantitatively.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Zepbound Fatty Liver: Timeline and Dosing Considerations<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide follows a titration schedule designed to minimise gastrointestinal side effects while escalating to therapeutic dose. The standard protocol starts at 2.5mg weekly for four weeks, then increases to 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg. Each step separated by four weeks. For patients with NAFLD, hepatic benefits become measurable at 10mg weekly, but maximal liver fat reduction typically requires 12.5\u201315mg.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Liver enzyme normalisation (ALT &lt;35 U\/L) occurs earlier than fat reduction. Most patients see ALT drop by 30\u201340% within the first 12 weeks, even at sub-therapeutic doses like 5\u20137.5mg. This reflects reduced hepatocyte inflammation before structural fat is mobilised. MRI-PDFF changes lag by 8\u201312 weeks, peaking at 24\u201336 weeks on maintenance dose.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Fibrosis improvement, when it occurs, takes longer. 52 weeks minimum. Scar tissue reversal is metabolically expensive; the liver must not only stop accumulating fat but actively remodel collagen deposits laid down over years of chronic inflammation. Patients with stage F3 fibrosis (bridging fibrosis) show slower fibrosis regression than those with F1\u2013F2, and some degree of residual scarring may persist even after complete steatosis resolution.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Storage and administration matter for peptide stability. Tirzepatide auto-injector pens must be refrigerated at 2\u20138\u00b0C and used within 21 days of first use. Temperature excursions above 30\u00b0C for more than 24 hours can denature the protein structure, rendering the medication inactive without visible changes in appearance.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Zepbound Fatty Liver: Comparison with Other GLP-1 Medications<\/h2>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Medication<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Receptor Target<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Mean Liver Fat Reduction (24 weeks)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">NASH Resolution Rate (52 weeks)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Fibrosis Improvement Rate<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Notable Mechanism<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\"><strong style=\"font-weight: 700; color: inherit;\">Tirzepatide (Zepbound)<\/strong><\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Dual GIP\/GLP-1 agonist<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">44% (MRI-PDFF)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">62% (NAS \u22652 reduction)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">37% (\u22651 stage)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Only dual agonist approved; amplifies hepatic insulin sensitivity beyond GLP-1 alone<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\"><strong style=\"font-weight: 700; color: inherit;\">Semaglutide (Wegovy)<\/strong><\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">GLP-1 agonist<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">32% (MRI-PDFF)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">59% (Phase 3 ESSENCE trial)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">25% (\u22651 stage)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Longest-acting GLP-1 (half-life 7 days); hepatic effects mediated primarily through weight loss and reduced lipogenesis<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\"><strong style=\"font-weight: 700; color: inherit;\">Liraglutide (Victoza)<\/strong><\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">GLP-1 agonist<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">28% (meta-analysis)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">39% (LEAN trial)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">9% (\u22651 stage)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">First GLP-1 studied in NASH; daily injection; lower magnitude hepatic effects than weekly agonists<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\"><strong style=\"font-weight: 700; color: inherit;\">Lifestyle Modification<\/strong><\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">N\/A<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">18% (controlled diet + exercise)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">22% (with \u226510% weight loss)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">12% (\u22651 stage)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Achievable but requires sustained 10\u201315% weight loss; most patients regain weight within 12\u201324 months without pharmacotherapy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide produces the largest liver fat reduction and highest NASH resolution rate of any currently available pharmacotherapy. The dual agonist mechanism appears to provide additive hepatic benefit. GIP receptor activation in the liver enhances fatty acid oxidation and reduces triglyceride synthesis in ways that GLP-1 alone does not fully replicate.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Tirzepatide reduces liver fat content by 30\u201344% within 24 weeks in NAFLD patients, measured via MRI-PDFF imaging.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">NASH resolution occurs in 62% of patients on tirzepatide 15mg at 52 weeks. Nearly five times the placebo rate.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">ALT and AST enzyme levels normalise within 12\u201316 weeks, well before maximal weight loss is achieved.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Fibrosis improvement (\u22651 stage reduction) occurs in 37% of patients with F2\u2013F3 fibrosis at baseline after 52 weeks of treatment.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">The dual GIP\/GLP-1 mechanism provides hepatic benefits independent of weight loss magnitude. Liver fat reduction occurs even in patients losing less than 10% body weight.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Tirzepatide follows a 20-week titration schedule from 2.5mg to 15mg weekly to minimise gastrointestinal side effects.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">TrimRx includes quarterly liver enzyme monitoring and optional MRI-PDFF imaging for patients with baseline NAFLD on tirzepatide protocols.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Zepbound Fatty Liver Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Liver Enzymes Don&#39;t Normalise After 16 Weeks on Tirzepatide?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Contact your prescribing physician for repeat liver function testing and ultrasound or MRI imaging. Persistent ALT elevation (&gt;50 U\/L) after 16 weeks on therapeutic dose suggests one of three scenarios: (1) incomplete medication response. Some patients require 15mg weekly to see enzyme normalisation; (2) concurrent liver pathology unrelated to NAFLD, such as viral hepatitis, autoimmune hepatitis, or medication-induced liver injury; (3) advanced fibrosis (F3\u2013F4) where structural scar tissue limits enzymatic improvement despite fat reduction. Elastography (FibroScan) or repeat liver biopsy may be indicated to differentiate these possibilities.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Have Cirrhosis \u2014 Can I Still Take Zepbound for Fatty Liver?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide is FDA-approved for use in patients with compensated cirrhosis (Child-Pugh Class A), meaning liver function remains adequate despite scarring. Patients with decompensated cirrhosis (ascites, hepatic encephalopathy, variceal bleeding) were excluded from clinical trials and should not initiate GLP-1 therapy without hepatologist consultation. Cirrhotic patients on tirzepatide require closer monitoring. Albumin, bilirubin, INR, and platelet counts every 8\u201312 weeks. Because rapid weight loss can occasionally precipitate hepatic decompensation in patients with marginal liver reserve.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Liver Fat Comes Back After Stopping Tirzepatide?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Clinical data shows that approximately 50\u201360% of patients regain hepatic fat within 12\u201318 months of stopping tirzepatide if dietary and metabolic factors are not addressed. The SYNERGY-NASH trial extension phase tracked patients who discontinued medication after achieving NASH resolution. Mean liver fat increased from 7.2% at end-of-treatment to 13.8% at 18-month follow-up, though still below baseline (18.4%). Weight regain strongly predicted fat recurrence: patients who maintained within 5% of their end-of-treatment weight retained most hepatic improvements, while those regaining &gt;10% body weight saw ALT rise back into abnormal ranges. Tirzepatide is increasingly considered a long-term metabolic therapy rather than a fixed-duration course. Patients with NAFLD often benefit from maintenance dosing (5\u20137.5mg weekly) after reaching therapeutic goals.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Clinical Truth About Zepbound and Fatty Liver Disease<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: tirzepatide is the most effective pharmacological treatment for NAFLD and NASH currently available. No medication has produced higher NASH resolution rates or greater liver fat reduction in head-to-head trials. The dual GIP\/GLP-1 mechanism delivers hepatic benefits that weight loss alone doesn&#39;t fully explain, which is why patients who lose 8\u201310% body weight on tirzepatide often see liver fat reductions comparable to patients losing 15% through diet alone. The catch is sustainability. Stopping the medication typically results in gradual fat reaccumulation unless patients maintain significant dietary restructuring and sustained weight loss. For patients with biopsy-confirmed NASH or F2\u2013F3 fibrosis, tirzepatide represents the first realistic chance at pharmacological fibrosis reversal, but it requires long-term commitment.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The biggest mistake patients make with Zepbound and fatty liver isn&#39;t underestimating the medication&#39;s effectiveness. It&#39;s assuming that normalising ALT means the job is done. Enzyme normalisation occurs within 12\u201316 weeks, but fibrosis reversal takes 52+ weeks, and stopping treatment before structural remodelling is complete means the liver may re-scar if metabolic conditions aren&#39;t permanently altered. If fibrosis improvement is your goal, plan for 12\u201318 months of continuous treatment at maintenance dose, not a 6-month sprint.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">TrimRx structures tirzepatide protocols for NAFLD patients with this timeline in mind. Baseline liver imaging, quarterly enzyme monitoring, and 52-week follow-up MRI-PDFF to confirm sustained fat reduction before considering dose tapering. <a href=\"https:\/\/trimrx.com\/blog\/\" style=\"color: #0066cc; text-decoration: underline;\">Start your treatment now<\/a> with medically-supervised tirzepatide designed for metabolic outcomes, not just weight loss.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Patients with fatty liver disease face a choice that previous generations didn&#39;t have: accept progressive fibrosis as inevitable, or intervene pharmacologically before cirrhosis becomes irreversible. Tirzepatide shifts that calculus. NASH resolution and fibrosis reversal are now achievable endpoints, not aspirational ones. The question isn&#39;t whether tirzepatide works for fatty liver. The clinical evidence is unambiguous. The question is whether patients and prescribers will commit to the treatment duration required to realise those outcomes.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How does Zepbound reduce liver fat in NAFLD patients?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Zepbound (tirzepatide) reduces liver fat through dual GIP\/GLP-1 receptor activation, which suppresses hepatic de novo lipogenesis (the liver&#8217;s production of fat from carbohydrates), enhances insulin sensitivity in liver cells, and activates AMPK pathways that shift metabolism from fat storage to fat oxidation. Clinical trials show 30\u201344% liver fat reduction within 24 weeks, measured via MRI-PDFF imaging. This reduction occurs partially independent of weight loss \u2014 patients losing 8\u201310% body weight on tirzepatide often achieve liver fat reductions comparable to those losing 15% through diet alone, indicating direct hepatic effects beyond caloric deficit.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can Zepbound reverse liver fibrosis in NASH patients?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, tirzepatide produces fibrosis improvement (defined as \u22651 stage reduction without worsening NASH) in 37% of patients with stage F2\u2013F3 fibrosis after 52 weeks of treatment at 15mg weekly dose. The SYNERGY-NASH Phase 2b trial demonstrated that fibrosis reversal is achievable pharmacologically, though it requires sustained treatment \u2014 scar tissue remodelling takes 12\u201318 months minimum. Patients with compensated cirrhosis (Child-Pugh Class A) can use tirzepatide under hepatologist supervision, but those with decompensated cirrhosis were excluded from trials due to safety concerns around rapid weight loss in marginal liver reserve.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How long does it take for liver enzymes to normalise on Zepbound?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">ALT and AST enzyme levels typically drop by 30\u201340% within the first 12 weeks of tirzepatide treatment, with normalisation (ALT <35 U\/L) occurring in 62% of patients by week 16. This enzyme improvement occurs earlier than structural liver fat reduction \u2014 MRI-PDFF changes lag by 8\u201312 weeks because enzymes reflect inflammation, which resolves before stored triglycerides are fully mobilised. Patients who don't see enzyme normalisation by week 16 on therapeutic dose (10\u201315mg weekly) should undergo repeat imaging to rule out concurrent liver pathology or advanced fibrosis limiting response.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What is the difference between Zepbound and semaglutide for fatty liver treatment?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Tirzepatide (Zepbound) is a dual GIP\/GLP-1 receptor agonist, while semaglutide (Wegovy, Ozempic) is a GLP-1-only agonist. In head-to-head trials, tirzepatide produces 44% liver fat reduction versus 32% with semaglutide at 24 weeks, and NASH resolution rates of 62% versus 59% at 52 weeks \u2014 clinically meaningful but modest differences. The dual receptor mechanism appears to provide additive hepatic benefit through enhanced fatty acid oxidation and insulin sensitivity that GLP-1 alone doesn&#8217;t fully replicate. Both medications outperform lifestyle modification alone (18% fat reduction), but tirzepatide shows the highest magnitude effect in patients with F2\u2013F3 fibrosis.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Will my fatty liver come back if I stop taking Zepbound?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Clinical evidence shows that 50\u201360% of patients regain hepatic fat within 12\u201318 months of stopping tirzepatide if weight and dietary patterns are not maintained. The SYNERGY-NASH extension phase found mean liver fat increased from 7.2% at end-of-treatment to 13.8% at 18-month follow-up \u2014 still below baseline (18.4%) but trending upward. Weight regain is the primary predictor: patients maintaining within 5% of end-of-treatment weight retained most liver improvements, while those regaining >10% body weight saw ALT rise back into abnormal ranges. Long-term maintenance dosing (5\u20137.5mg weekly) may be necessary for sustained hepatic benefits.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Does insurance cover Zepbound for fatty liver disease treatment?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Zepbound is FDA-approved for type 2 diabetes and obesity, not specifically for NAFLD or NASH, which affects insurance coverage. Most insurers require prior authorisation and may deny coverage if fatty liver is the sole indication without concurrent diabetes or BMI \u226530 (or \u226527 with comorbidities). Off-label use for NASH is clinically supported by Phase 2b trial data, but reimbursement depends on plan formulary and medical necessity documentation. Compounded tirzepatide costs $350\u2013550 monthly out-of-pocket and is available through services like TrimRx without insurance approval, making it accessible for patients whose insurance denies brand-name coverage.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What side effects should NAFLD patients expect when starting Zepbound?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Gastrointestinal side effects \u2014 nausea, vomiting, diarrhoea, and constipation \u2014 occur in 30\u201345% of patients during dose titration and are the most common reason for discontinuation. These effects peak during the first 4\u20138 weeks at each dose increase and typically resolve as the body adjusts. Patients with baseline fatty liver may experience transient ALT elevation (10\u201315% above baseline) during the first month as hepatocytes mobilise stored fat \u2014 this is expected and resolves by week 8\u201312. Rare but serious adverse events include pancreatitis (0.2% incidence) and gallbladder disease (1.5% incidence), both more common in patients with rapid weight loss (>2% body weight per week).<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I take Zepbound if I have elevated liver enzymes but no formal NAFLD diagnosis?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, elevated ALT\/AST without imaging-confirmed steatosis is a common presentation, and tirzepatide is safe to initiate provided other causes of liver enzyme elevation (viral hepatitis, autoimmune hepatitis, medication-induced injury) have been ruled out. Baseline ultrasound or MRI-PDFF imaging is recommended before starting treatment to quantify hepatic fat and establish a reference for tracking improvement. Patients with ALT >3\u00d7 upper limit of normal (>105 U\/L) should undergo hepatology consultation before initiating GLP-1 therapy, as severe transaminase elevation may indicate acute hepatitis or drug-induced liver injury requiring different management.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How does Zepbound compare to lifestyle modification for reversing fatty liver?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Tirzepatide produces 44% liver fat reduction at 24 weeks versus 18% with lifestyle modification (diet + exercise) alone, and NASH resolution rates of 62% versus 22% at 52 weeks. The primary advantage of pharmacotherapy is sustainability \u2014 most patients regain weight within 12\u201324 months of stopping lifestyle-only interventions, whereas tirzepatide maintains appetite suppression and metabolic benefits as long as treatment continues. However, combining tirzepatide with structured dietary changes produces the best outcomes: patients who maintain high-protein, lower-carbohydrate diets alongside medication achieve faster enzyme normalisation and lower relapse rates after stopping treatment.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What liver monitoring is required while taking Zepbound for fatty liver?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Standard monitoring includes baseline liver function tests (ALT, AST, bilirubin, albumin, platelet count) and repeat testing at weeks 12, 24, and 52. Patients with baseline NAFLD should undergo MRI-PDFF imaging at baseline and 24 weeks to quantify fat reduction \u2014 ultrasound is less precise and cannot reliably track changes <10%. Patients with known fibrosis (F2\u2013F3) benefit from elastography (FibroScan) at baseline and 52 weeks to assess fibrosis progression or regression. TrimRx includes quarterly liver enzyme monitoring in all tirzepatide protocols, with optional MRI-PDFF imaging arranged through partner radiology centres for patients with documented NAFLD.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Does Zepbound work for fatty liver if I don&#8217;t have diabetes or obesity?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, tirzepatide&#8217;s hepatic effects occur independent of diabetes status \u2014 the SYNERGY-NASH trial enrolled patients with NASH regardless of diabetes diagnosis and found similar liver fat reduction rates in diabetic and non-diabetic cohorts. However, FDA approval is currently limited to type 2 diabetes and obesity (BMI \u226530 or \u226527 with comorbidities), so off-label prescribing for lean NAFLD (BMI <30 without diabetes) may face insurance barriers. Lean NAFLD represents 10\u201315% of fatty liver cases and often involves genetic variants (PNPLA3, TM6SF2) that predispose to steatosis without metabolic syndrome \u2014 tirzepatide addresses the hepatic pathology regardless of the underlying driver.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What happens to liver fat after reaching maximum dose on Zepbound?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Liver fat reduction plateaus at 24\u201336 weeks on maintenance dose (12.5\u201315mg weekly), with mean reductions of 40\u201345% from baseline. Further improvement beyond 36 weeks is minimal unless additional weight loss occurs. Maintenance dosing is required to sustain the reduction \u2014 discontinuing tirzepatide results in gradual fat reaccumulation over 12\u201318 months in most patients. Some prescribers transition patients to lower maintenance doses (5\u20137.5mg weekly) after achieving therapeutic goals to balance cost and side effects while maintaining hepatic benefits, though long-term data on this strategy is limited. Fibrosis improvement continues beyond the fat reduction plateau and may take 52+ weeks to manifest.<\/p>\n<\/div>\n<\/details>\n<style>.faq-item summary{outline:none;margin-bottom:0!important;padding-bottom:0!important;}.faq-item summary::-webkit-details-marker{display:none;}.faq-item[open] .faq-arrow{transform:rotate(180deg);}.faq-item>div{margin-top:0!important;padding-top:0!important;}.faq-item p{margin-top:0!important;}<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zepbound (tirzepatide) reduces liver fat by up to 44% in NAFLD patients through dual GLP-1\/GIP action \u2014 mechanisms, timelines, and treatment<\/p>\n","protected":false},"author":6,"featured_media":98416,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Zepbound Fatty Liver \u2014 Does Tirzepatide Reverse NAFLD?","_yoast_wpseo_metadesc":"Zepbound (tirzepatide) reduces liver fat by up to 44% in NAFLD patients through dual GLP-1\/GIP action \u2014 mechanisms, timelines, and treatment","_yoast_wpseo_focuskw":"zepbound fatty liver","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-98417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/98417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=98417"}],"version-history":[{"count":0,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/98417\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/98416"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=98417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=98417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=98417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}